|

BC001+Sintilimab+XELOX Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.1

Indications

  • Advanced or Metastatic Gastric Cancer1
  • Gastroesophageal Junction Adenocarcinoma1
  • Cancer1

Other1 trial

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.